SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation

Qiang Zhang,Huajun Zhang,Kun Huang,Yong Yang,Xianfeng Hui,Jindong Gao,Xinglin He,Chengfei Li,Wenxiao Gong,Yufei Zhang,Cheng Peng,Xiaoxiao Gao,Huanchun Chen,Zhong Zou,Zhengli Shi,Meilin Jin
DOI: https://doi.org/10.1101/2020.04.01.021196
2020-04-03
Abstract:Summary Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, and rapidly spread worldwide. Previous studies suggested cat could be a potential susceptible animal of SARS-CoV-2. Here, we investigated the infection of SARS-CoV-2 in cats by detecting specific serum antibodies. A cohort of serum samples were collected from cats in Wuhan, including 102 sampled after COVID-19 outbreak, and 39 prior to the outbreak. 15 of 102 (14.7%) cat sera collected after the outbreak were positive for the receptor binding domain (RBD) of SARS-CoV-2 by indirect enzyme linked immunosorbent assay (ELISA). Among the positive samples, 11 had SARS-CoV-2 neutralizing antibodies with a titer ranging from 1/20 to 1/1080. No serological cross-reactivity was detected between the SARS-CoV-2 and type I or II feline infectious peritonitis virus (FIPV). Our data demonstrates that SARS-CoV-2 has infected cat population in Wuhan during the outbreak.
What problem does this paper attempt to address?